These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21829963)

  • 1. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.
    Morrison BF; Aiken WD; Reid ME
    Rev Panam Salud Publica; 2011 Jun; 29(6):404-8. PubMed ID: 21829963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
    Chon JK; Jacobs SC; Naslund MJ
    J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.
    Garje R; Chennamadhavuni A; Mott SL; Chambers IM; Gellhaus P; Zakharia Y; Brown JA
    Clin Genitourin Cancer; 2020 Apr; 18(2):e157-e166. PubMed ID: 31956009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
    Mariani AJ; Glover M; Arita S
    J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
    Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
    JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy for stage D cancer of the prostate.
    Gudziak MR; Smith AY
    West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
    Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
    BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
    J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
    Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
    Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic considerations in the treatment of prostate cancer.
    Varenhorst E; Carlsson P; Pedersen K
    Pharmacoeconomics; 1994 Aug; 6(2):127-41. PubMed ID: 10147438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.